Top

Published in:

Open Access 01-07-2018 | Original Article

Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis

Authors: Whitney W. Woodmansee, Murray B. Gordon, Mark E. Molitch, Adriana G. Ioachimescu, Don W. Carver, Beloo Mirakhur, David Cox, Roberto Salvatori

Published in: Endocrine | Issue 1/2018

Abstract

Purpose

This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline^® (lanreotide, LAN) Depot for Acromegaly (SODA) registry.

Methods

Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed.

Results

There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033).

Conclusions

Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.

T. Burton, E. Le Nestour, M. Neary, W.H. Ludlam, Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 19(3), 262–267 (2016). https://doi.org/10.1007/s11102-015-0701-2 CrossRefPubMedCentralPubMed

S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3), 294–302 (2013). https://doi.org/10.1007/s11102-012-0420-x CrossRefPubMed

S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). https://doi.org/10.1210/jc.2008-2421 CrossRefPubMed

L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr. Pract. 17, 1–44 (2011).CrossRefPubMed

A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010). https://doi.org/10.1210/jc.2009-2670 CrossRefPubMed

L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A.H. Wass, Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). https://doi.org/10.1210/jc.2014-2700 CrossRefPubMed

A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243–248 (2014). https://doi.org/10.1038/nrendo.2014.21 CrossRefPubMed

M. Sherlock, J. Ayuk, J.W. Tomlinson, A.A. Toogood, A. Aragon-Alonso, M.C. Sheppard, A.S. Bates, P.M. Stewart, Mortality in patients with pituitary disease. Endocr. Rev. 31(3), 301–342 (2010). https://doi.org/10.1210/er.2009-0033 CrossRefPubMed

M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. Lopez-Felix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99(12), 4438–4446 (2014). https://doi.org/10.1210/jc.2014-2670 CrossRefPubMed

10.

M.S. Broder, M.P. Neary, E. Chang, D. Cherepanov, L. Katznelson, Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4), 333–341 (2014). https://doi.org/10.1007/s11102-013-0506-0 CrossRefPubMed

11.

H. Placzek, Y. Xu, Y. Mu, S.M. Begelman, M. Fisher, Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J. Manag. Care Spec. Pharm. 21(12), 1106–1112 (2015)CrossRefPubMed

12.

F. Bogazzi, A. Colao, G. Rossi, M. Lombardi, C. Urbani, C. Sardella, A. Iannelli, I. Scattina, L. Manetti, S. Del Sarto, R. Pivonello, L.F.S. Grasso, I. Lupi, R.S. Auriemma, G. Lombardi, E. Martino, Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur. J. Endocrinol. 169(3), 367–376 (2013). https://doi.org/10.1530/eje-13-0166 CrossRefPubMed

13.

L. Varadhan, R.C. Reulen, M. Brown, R.N. Clayton, The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Pituitary 19(3), 251–261 (2016). https://doi.org/10.1007/s11102-015-0700-3 CrossRefPubMed

14.

N.R. Biermasz, A.M. Pereira, J.W. Smit, J.A. Romijn, F. Roelfsema, Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90(5), 2731–2739 (2005). https://doi.org/10.1210/jc.2004-2297 CrossRefPubMed

15.

O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a meta analysis. J. Clin. Endocrinol. Metab. 93(1), 61–67 (2008). https://doi.org/10.1210/jc.2007-1191 CrossRefPubMed

16.

I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89–95 (2008). https://doi.org/10.1530/eje-08-0267 CrossRefPubMed

17.

R. Salvatori, W.W. Woodmansee, M. Molitch, M.B. Gordon, K.G. Lomax, Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 17(1), 13–21 (2014). https://doi.org/10.1007/s11102-012-0460-2 CrossRefPubMed

18.

R. Salvatori, M.B. Gordon, W.W. Woodmansee, A.G. Ioachimescu, D.W. Carver, B. Mirakhur, D. Cox, M.E. Molitch, A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary 20(6), 605–618 (2017). https://doi.org/10.1007/s11102-017-0821-y CrossRefPubMed

19.

K.M.J.A. Claessen, S.R. Ramautar, A.M. Pereira, J.W.A. Smit, F. Roelfsema, J.A. Romijn, H.M. Kroon, M. Kloppenburg, N.R. Biermasz, Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur. J. Endocrinol. 167(2), 235–244 (2012). https://doi.org/10.1530/eje-12-0147 CrossRefPubMed

20.

M.V. Davi, L. Dalle Carbonare, A. Giustina, M. Ferrari, A. Frigo, V. Lo Cascio, G. Francia, Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159(5), 533–540 (2008). https://doi.org/10.1530/eje-08-0442 CrossRefPubMed

21.

M. Bex, R. Abs, G. T. Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157(4), 399–409 (2007). https://doi.org/10.1530/eje-07-0358 CrossRefPubMed

22.

T. Brue, F. Castinetti, F. Lundgren, M. Koltowska-Haggstrom, P. Petrossians, Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur. J. Endocrinol. 161, (Suppl 1), 11–S17 (2009). https://doi.org/10.1530/eje-09-0333 CrossRef

23.

A. Colao, R.S. Auriemma, M. Galdiero, G. Lombardi, R. Pivonello, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94(10), 3746–3756 (2009). https://doi.org/10.1210/jc.2009-0941 CrossRefPubMed

24.

A. Colao, R. Pivonello, L.F. Grasso, R.S. Auriemma, M. Galdiero, S. Savastano, G. Lombardi, Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur. J. Endocrinol. 165(5), 713–721 (2011). https://doi.org/10.1530/eje-11-0408 CrossRefPubMed

25.

A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1), 50–58 (2012). https://doi.org/10.1007/s11102-011-0318-z CrossRefPubMed

26.

R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3), 872–884 (2017). https://doi.org/10.1007/s12020-016-0995-5 CrossRefPubMed

27.

M. Sherlock, R.C. Reulen, A. Aragon-Alonso, J. Ayuk, R.N. Clayton, M.C. Sheppard, M.M. Hawkins, A.S. Bates, P.M. Stewart, A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J. Clin. Endocrinol. Metab. 99(2), 478–485 (2014). https://doi.org/10.1210/jc.2013-2450 CrossRefPubMed

28.

J.D. Carmichael, M.S. Broder, D. Cherepanov, E. Chang, A. Mamelak, Q. Said, M.P. Neary, V. Bonert, The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr. Disord. 17(1), 15 (2017). https://doi.org/10.1186/s12902-017-0166-6 CrossRefPubMedCentralPubMed

29.

L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. Garcia-Dominguez, A.A. Reza-Albarran, D. Cuevas-Ramos, V. Melgar, J. Talavera, A.J. Rivera-Hernandez, C.V. Valencia-Mendez, M. Mercado, The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101(11), 3997–4004 (2016). https://doi.org/10.1210/jc.2016-1937 CrossRefPubMed

30.

A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J.M. Gomez, I. Halperin, T. Lucas-Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004)CrossRefPubMed

31.

X. Guo, L. Gao, S. Zhang, Y. Li, Y. Wu, L. Fang, K. Deng, Y. Yao, W. Lian, R. Wang, B. Xing, Cardiovascular system changes and related risk factors in acromegaly patients: a case-control study. Int J. Endocrinol. 2015, 573643 (2015). https://doi.org/10.1155/2015/573643. doi: 573610.571155/572015/573643PubMedCentralCrossRefPubMed

32.

C.M. dos Santos Silva, I. Gottlieb, I. Volschan, L. Kasuki, L. Warszawski, G.A. Balarini Lima, S.S. Xavier, R.C. Pedrosa, L.V. Neto, M.R. Gadelha, Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J. Clin. Endocrinol. Metab. 100(12), 4447–4455 (2015). https://doi.org/10.1210/jc.2015-2675 CrossRefPubMed

33.

A.S. Powlson, M. Gurnell, Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 103(1), 75–85 (2016). https://doi.org/10.1159/000438903 CrossRefPubMed

34.

P. Attal, P. Chanson, Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95(2), 483–495 (2010). https://doi.org/10.1210/jc.2009-1912 CrossRefPubMed

35.

L.M. Galerneau, J.L. Pepin, A.L. Borel, O. Chabre, M. Sapene, B. Stach, J. Girey-Rannaud, N. Arnol, R. Tamisier, P. Caron, Acromegaly in sleep apnoea patients: a large observational study of 755 patients. Eur. Respir. J. 48(5), 1489–1492 (2016). https://doi.org/10.1183/13993003.01229-2016 CrossRefPubMed

36.

S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 164(6), 877–884 (2011). https://doi.org/10.1530/eje-10-1050 CrossRefPubMed

37.

C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res 48(5), 299–305 (2016). https://doi.org/10.1055/s-0035-1569277 CrossRefPubMed

38.

C. Wen-Ko, C. Szu-Tah, L. Feng-Hsuan, C. Chen-Nen, W. Ming-Hsu, L. Jen-Der, The impact of diabetes mellitus on the survival of patients with acromegaly. Endokrynol. Pol. 67(5), 501–506 (2016). https://doi.org/10.5603/EP.a2016.0031 CrossRefPubMed

39.

G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a meta analysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500–1508 (2009). https://doi.org/10.1210/jc.2008-2332 CrossRefPubMed

40.

C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169(1), 99–108 (2013). https://doi.org/10.1530/eje-13-0032 CrossRefPubMed

41.

P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Prévost, P. Maisonobe, A. Clermont, Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99(4), 1282–1290 (2014). https://doi.org/10.1210/jc.2013-3318 CrossRefPubMed

42.

P.J. Caron, S. Petersenn, A. Houchard, C. Sert, J.S. Bevan, Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study. Clin. Endocrinol. (Oxf.) 86(4), 541–551 (2017). https://doi.org/10.1111/cen.13285 CrossRef

43.

H.A. Schmid, T. Brue, A. Colao, M.R. Gadelha, I. Shimon, K. Kapur, A.M. Pedroncelli, M. Fleseriu, Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53, 210–219 (2016). https://doi.org/10.1007/s12020-016-0895-8 CrossRefPubMedCentralPubMed

44.

K.C. Leung, N. Doyle, M. Ballesteros, M.J. Waters, K.K. Ho, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85(12), 4712–4720 (2000). https://doi.org/10.1210/jcem.85.12.7017 CrossRefPubMed

45.

A. Ciresi, M.C. Amato, R. Pivonello, E. Nazzari, L.F. Grasso, F. Minuto, D. Ferone, A. Colao, C. Giordano, The metabolic profile in active acromegaly is gender-specific. J. Clin. Endocrinol. Metab. 98(1), E51–E59 (2013). https://doi.org/10.1210/jc.2012-2896 CrossRefPubMed

46.

H.K. Gleeson, C.A. Lissett, S.M. Shalet, Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J. Clin. Endocrinol. Metab. 90(2), 1061–1067 (2005). https://doi.org/10.1210/jc.2004-0501 CrossRefPubMed

47.

S.Y. Nam, E.J. Lee, K.R. Kim, H.C. Lee, M.S. Nam, J.H. Cho, K.B. Huh, Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity. Metabolism 45(5), 594–597 (1996). https://doi.org/10.1016/S0026-0495(96)90029-3 CrossRefPubMed

48.

M. Matta, V. Bongard, S. Grunenwald, J.-C. Maiza, A. Bennet, P. Caron, Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Eur. J. Endocrinol. 164(6), 885–889 (2011). https://doi.org/10.1530/eje-11-0098 CrossRefPubMed

49.

T. Rokkas, D. Pistiolas, P. Sechopoulos, G. Margantinis, G. Koukoulis, Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis. World J. Gastroenterol. 14(22), 3484–3489 (2008). https://doi.org/10.3748/wjg.14.3484 CrossRefPubMedCentralPubMed

50.

A.G. Renehan, J. O’Connell, D. O’Halloran, F. Shanahan, C.S. Potten, S.T. O’Dwyer, S.M. Shalet, Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm. Metab. Res. 35(11-12), 712–725 (2003). https://doi.org/10.1055/s-2004-814150 CrossRefPubMed

51.

O. Manousos, J. Souglakos, C. Bosetti, A. Tzonou, V. Chatzidakis, D. Trichopoulos, H.O. Adami, C. Mantzoros, IGF-I and IGF-II in relation to colorectal cancer. Int. J. Cancer 83(1), 15–17 (1999)CrossRefPubMed

52.

P.J. Jenkins, P.D. Fairclough, Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 51(suppl 5), v13–v14 (2002). https://doi.org/10.1136/gut.51.suppl_5.v13 CrossRefPubMedCentralPubMed

53.

D. Dworakowska, M. Gueorguiev, P. Kelly, J.P. Monson, G.M. Besser, S.L. Chew, S.A. Akker, W.M. Drake, P.D. Fairclough, A.B. Grossman, P.J. Jenkins, Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur. J. Endocrinol. 163(1), 21–28 (2010). https://doi.org/10.1530/eje-09-1080 CrossRefPubMed

54.

M.B. Gordon, S. Nakhle, W.H. Ludlam, Patients with acromegaly presenting with colon cancer: a case series.Case Rep. Endocrinol. 2016, 4 (2016). https://doi.org/10.1155/2016/5156295 CrossRef

55.

P. Agarwal, P. Rai, M. Jain, S. Mishra, U. Singh, S.K. Gupta, Prevalence of colonic polyp and its predictors in patients with acromegaly. Indian J. Endocrinol. Metab. 20(4), 437–442 (2016). https://doi.org/10.4103/2230-8210.183455 CrossRefPubMedCentralPubMed

56.

S. Petersenn, M. Buchfelder, B. Gerbert, H. Franz, H.J. Quabbe, H.M. Schulte, M. Grussendorf, M. Reincke, Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin. Endocrinol. (Oxf.) 71(3), 400–405 (2009). https://doi.org/10.1111/j.1365-2265.2009.03547.x CrossRef

57.

M. Sherlock, R.C. Reulen, A.A. Alonso, J. Ayuk, R.N. Clayton, M.C. Sheppard, M.M. Hawkins, A.S. Bates, P.M. Stewart, ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 94(11), 4216–4223 (2009). https://doi.org/10.1210/jc.2009-1097 CrossRefPubMed

58.

A.K. Annamalai, E.L. Gayton, A. Webb, D.J. Halsall, C. Rice, F. Ibram, A.N. Chaudhry, H.L. Simpson, L. Berman, M. Gurnell, Increased prevalence of gallbladder polyps in acromegaly. J. Clin. Endocrinol. Metab. 96(7), E1120–E1125 (2011). https://doi.org/10.1210/jc.2010-2669 CrossRefPubMed

Title: Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis
Authors: Whitney W. Woodmansee
Murray B. Gordon
Mark E. Molitch
Adriana G. Ioachimescu
Don W. Carver
Beloo Mirakhur
David Cox
Roberto Salvatori
Publication date: 01-07-2018
Publisher: Springer US
Published in: Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1615-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Comment on Microsurgical therapy of pituitary adenomas

Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?

Comparison of peripheral nerve protection between insulin-based glucose control and alpha lipoic acid (ALA) in the streptozotocin (STZ)-induced diabetic rat

Lactate induces expression and secretion of fibroblast growth factor-21 by muscle cells

Standardization of simple auxiliary method beneficial to total endoscopic thyroidectomy on patients with PTC, based on retrospective study of 356 cases

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page